Tyra Biosciences SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company developing FGFR-focused precision medicines. Recent 8-K reports cover operating results, clinical-program updates for TYRA-300/dabogratinib, officer and board appointments, and capital actions under a registered at-the-market offering program.
Proxy materials describe annual meeting voting matters, board structure and corporate-governance procedures. Registration-linked disclosures and material-event reports also identify TYRA common stock, equity issuance activity, and the company’s use of SEC exhibits for press releases and other official corporate records.
Tyra Biosciences, Inc. reported a Form 4 showing a grant of stock options to non-employee director Jake Simson, held for the benefit of RA Capital-managed entities. The award covers 13,160 options for common stock at an exercise price of $32.68 per share and was received for no cash cost.
The options were granted under the company’s Non-Employee Director Compensation Program. One-twelfth of the award vests monthly after May 28, 2026, with any remaining unvested portion vesting at the next annual stockholder meeting if it occurs within a year, subject to Mr. Simson’s continued service.
Under Mr. Simson’s arrangement with RA Capital Management, any net cash or stock from exercising these options must be turned over to the adviser for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund, and a separately managed account, and the reporting persons disclaim beneficial ownership except for any pecuniary interest.
Tyra Biosciences director Rehan Verjee received a stock option grant covering 13,160 shares of common stock, with an exercise price of $32.68 per share. The option was granted under the Non-Employee Director Compensation Program and vests in 12 equal monthly installments after May 28, 2026, with any remaining unvested portion vesting at the next annual stockholder meeting if it occurs within a year and service continues. Following this award, Verjee holds options for 13,160 shares.
Tyra Biosciences director Susan Moran received a grant of stock options covering 13,160 shares of common stock. The options have an exercise price of $32.68 per share and were granted under the company’s Non-Employee Director Compensation Program as equity compensation.
The options vest over time: 1/12 of the 13,160 shares vest monthly after the May 28, 2026 grant date. If the next annual stockholder meeting occurs before the first anniversary of the grant, any remaining unvested options vest at that meeting, provided she continues serving the company. Following this grant, she holds 13,160 options directly.
Tyra Biosciences, Inc. reported a Form 4 showing a stock option grant covering 13,160 shares of Common Stock to director Jake Simson under the company’s Non-Employee Director Compensation Program. The option has an exercise price of $32.68 per share and expires on May 27, 2036. One-twelfth of the option vests monthly after the May 28, 2026 grant date, with any remaining unvested portion vesting at the next annual stockholder meeting if it occurs within the first year, subject to continued service. Under Simson’s arrangement with RA Capital Management, L.P., the option is held for the benefit of RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., and a separately managed account, and any net cash or stock from exercise must be turned over to RA Capital, so Simson disclaims beneficial ownership of the option and the underlying shares.
Tyra Biosciences director Adele M. Gulfo received a stock option grant for 13,160 shares of common stock at an exercise price of $32.68 per share. This award was issued under the company’s Non-Employee Director Compensation Program and represents compensation rather than an open-market purchase.
The option vests over time: one-twelfth of the shares vest monthly after the May 28, 2026 grant date. If the next annual shareholder meeting occurs before the first anniversary of the grant, any remaining unvested portion will vest on that meeting date, provided she continues serving the company through each vesting date.
Tyra Biosciences director Robert J. More received a grant of stock options covering 13,160 shares of common stock at an exercise price of $32.68 per share. The options expire on May 27, 2036 and vest in 12 equal monthly installments after May 28, 2026. Any remaining unvested portion will fully vest at the next annual stockholder meeting if it occurs before the first anniversary of the grant date, subject to his continuous service.
Tyra Biosciences director Stephen Michael Rothenberg received a new stock option grant covering 13,160 shares of common stock. The options have an exercise price of $32.68 per share and expire on May 27, 2036. The grant was made under the company’s Non-Employee Director Compensation Program.
Vesting is structured so that 1/12 of the option vests monthly after the May 28, 2026 grant date. If the next annual stockholder meeting occurs before the first anniversary of grant, any remaining unvested portion vests on that meeting date, subject to continued service.
Tyra Biosciences, Inc. amendment to a Schedule 13G/A reports that Commodore Capital entities and two managing partners beneficially own 2,475,000 shares of Common Stock as of March 31, 2026. The filing states this equals 4.2% of the class using 59,469,687 shares outstanding as of March 31, 2026.
The report attributes the position to Commodore Capital LP and Commodore Capital Master LP, with Michael Kramarz and Robert Egen Atkinson identified as managing partners exercising investment discretion. The filing is signed and dated May 15, 2026.
Tyra Biosciences, Inc. holdings disclosed by Janus Henderson Group plc via an amended Schedule 13G/A reporting 3,890,589 common shares, representing 7.2% of the class. The filing states the Asset Managers exercise shared voting and dispositive power over these shares.
The disclosure clarifies the Asset Managers act on behalf of Managed Portfolios and disclaim rights to receive dividends or sale proceeds; signature dated 5/15/2026.